Call Us Now! A simple phone call today could save your life! 1 (800) 205-8101

Sampling of Cell Therapy Published Studies

Over one thousand medical papers have been written on stem cell transplantation; here are just a few of the distilled results:

  • W. Boecker directed a double-blind clinical trial on 146 patients with cirrhosis of the liver. Half were given a placebo, and half took liver cells. Sixty-seven percent (67%) of those taking the liver cells had significant improvement in their liver function over the placebo.
  • In another double-blind study of 600 patients suffering from hepatitis, Dr. Kiyoshi Fujisawa at the Jikei University School of Medicine in Tokyo, showed that, in only 12 weeks, 35% of the patients taking a liver cells showed substantial improvement over the placebo. He stated, "The results of this study clearly demonstrate that oral administration of liver hydrolysate preparations can be useful in the treatment of chronic hepatitis, and this efficacy is thought to derive from improved function of damaged hepatocytes and from subsidence of active changes of the liver.
  • Pietro Cazzola conducted a study of 130 patients with malfunctions of theimmune system and reported that treating those patients with thymus gland cells improved their conditions.
  • D.M. Kouttab of the Roger Williams Hospital and Brown University reported health efficacy for cells of the adrenal cortex.
  • Franco Pandolfi at the University of Rome directed a double-blind clinical trial on elderly hospitalized patients. Half of the patients were given a thymus cells and one half took a placebo. Those taking the cells had fewer infections over a six-month period than those receiving the placebo.
  • V. Cangemi followed 25 patients taking thymus cells after cancer surgery and found that none got infections. Tests showed that their immune systems were substantially bolstered by the thymus cells compared to controls.
  • Massimo Fedrico guided a double-blind clinical trial of 134 people undergoing chemotherapy. Half of the patients were given thymus cells, living 49% longer than those taking a placebo.
  • Alec Fiocchi led a double-blind clinical trial on patients with chronic respiratory infections. Half of the patients were given thymus cells, and the other half received placebos. In only three months, but not during the winter cold season, those taking the thymus cells had 30% fewer infections than the placebo group.
  • Tuftsin is a peptide found in spleen cells. Dr. I. Florentin reported in the journal, Cancer Immunology, that laboratory animals given tuftsin showed a significant 3.1 fold increase of disease-fighting cells. Dr. M.S. Wleklik found that even the tiniest amount of tuftsin in vitro stimulated the production of TNF lymphokines. These lymphokines are killers of tumor cells. Dr. M. Bruley-Rosset gave elderly mice tuftsin for a few months, reporting in the Annals of the New York Academy of Sciences, that the capacity of disease-fighting macrophages in these old mice was restored to the level of much younger mice. Dr. M. Fridkin found that a deficiency of tuftsin is commonly found in people who get frequent infections as well as in cancer patients. AIDS patients also have very little tuftsin in their systems.
  • Calf heart cells have 17 amino acids, five B vitamins, folic acid, calcium, iron, heparin, coenzyme Q10, cytochrome C and mesoglycan. A clinical study of the use of calf aorta in patients affected by chronic atherosclerotic arteriopathies showed a significant increase in femoral venous blood flow and an anticoagulant activity.
  • Laurora and researchers from the Cardiovascular Institute conducted double-blind trials on patients with early stages of arteriosclerosis (clogged arteries). Half of the patients received mesoglycan, and half took a placebo. A small section of one artery was scanned with high-resolution ultrasound before and after treatment. At the end of 18 months, the occlusion of the arteries of the patients taking the placebo had increased seven times more than those takingmesoglycan. Several clinical trials have shown that mesoglycan also deters blood clots and reduces the risk of strokes even for people who have severely clogged arteries. Dr. Vecchio found that patients given mesoglycan for only 15 days experienced a 20% drop in "bad" cholesterol and 44% increase in "good" cholesterol.
  • To Hear from a ProGenaCell Representative

    Fill out an Information Request Form Today! How can we help?